Detalles de la búsqueda
1.
A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer.
BMC Med
; 22(1): 13, 2024 01 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38212842
2.
Impacts of systemic treatments on health-related quality of life for patients with metastatic colorectal cancer: a systematic review and network meta-analysis.
BMC Cancer
; 24(1): 188, 2024 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38336718
3.
Identifying optimal ALK inhibitors in first- and second-line treatment of patients with advanced ALK-positive non-small-cell lung cancer: a systematic review and network meta-analysis.
BMC Cancer
; 24(1): 186, 2024 Feb 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38331773
4.
QALY-type preference and willingness-to-pay among end-of-life patients with cancer treatments: a pilot study using discrete choice experiment.
Qual Life Res
; 33(3): 753-765, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38079024
5.
Estimating the cost-effectiveness threshold of advanced non-small cell lung cancer in China using mean opportunity cost and contingent valuation method.
Cost Eff Resour Alloc
; 21(1): 80, 2023 Nov 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37915053
6.
Cost-effectiveness and potential budget impact of non-pharmacological interventions for early management in prehypertensive people: an economic evaluation for China.
BMC Public Health
; 23(1): 1531, 2023 08 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37568086
7.
Economic evaluation of five first-line PD-(L)1 inhibitors for treating non-squamous non-small cell lung cancer in China: A cost-effectiveness analysis based on network meta-analysis.
Front Pharmacol
; 14: 1119906, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37021058
8.
Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model.
Front Public Health
; 11: 1051484, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36908446
9.
Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing.
BioDrugs
; 37(3): 421-432, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36840914
10.
Sotorasib versus Docetaxel for treatment of US and Chinese patients with advanced non-small-cell lung cancer with KRAS p.G12C-mutated: A cost-effectiveness analysis to inform drug pricing.
Medicine (Baltimore)
; 102(50): e36387, 2023 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38115313
11.
Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067.
Pharmacoecon Open
; 7(3): 383-392, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36757569
12.
Cost-effectiveness analysis of atezolizumab in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen: a United Kingdom health care perspective.
Front Public Health
; 11: 1282374, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37841712
13.
Hypoxemia in thoracoscopic lung resection surgery using a video double-lumen tube versus a conventional double-lumen tube: A propensity score-matched analysis.
Front Surg
; 10: 1090233, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36874459
14.
Traffic Flow Prediction and Analysis in Smart Cities Based on the WND-LSTM Model.
Comput Intell Neurosci
; 2022: 7079045, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35958752
15.
Effectiveness and Cost-Effectiveness of Non-Pharmacological Interventions among Chinese Adults with Prediabetes: A Protocol for Network Meta-Analysis and CHIME-Modeled Cost-Effectiveness Analysis.
Int J Environ Res Public Health
; 19(3)2022 01 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-35162645
16.
A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer.
Front Immunol
; 13: 948597, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36389713
17.
Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China.
Front Public Health
; 10: 912921, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36045725
18.
Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma.
Front Oncol
; 12: 953671, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36561521
19.
Economic Evaluation of Nemonoxacin, Moxifloxacin and Levofloxacin in the Treatment of Early Community-Acquired Pneumonia with Possible Pulmonary Tuberculosis.
Int J Environ Res Public Health
; 19(8)2022 04 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35457683
20.
Identifying optimal PD-1/PD-L1 inhibitors in first-line treatment of patients with advanced squamous non-small cell lung cancer in China: Updated systematic review and network meta-analysis.
Front Pharmacol
; 13: 910656, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36249794